Nitsche, Mirko

[["dc.bibliographiccitation.firstpage","195"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.lastpage","202"],["dc.bibliographiccitation.volume","183"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Fest, Jan"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Gruendker, Carsten"],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Schmidberger, Heinz"],["dc.date.accessioned","2018-11-07T11:03:57Z"],["dc.date.available","2018-11-07T11:03:57Z"],["dc.date.issued","2007"],["dc.description.abstract","Background and Purpose: Simultaneous radiotherapy with chemotherapy is a standard treatment for inoperable non-small cell lung cancer (NSCLC), but the clinical outcome still remains poor. To further intensify treatment, substances need to be identified, which increase the effect of radiation on tumor cells without further enhancing toxicity to normal tissue. Hormones have a different toxicity profile than radiation or cytostatic drugs. As NSCLC often express estrogen receptors (ERs), the combination of genistein or estradiol and radiation in vitro was investigated. Material and Methods: A549 NSCLC cells with an inducible expression of a mutated TP53 and fibroblasts of a male donor (DF-18) were examined. ER expression was immunocytologically confirmed in all studied cell lines. Clonogenic survival was measured after incubation of the cells with genistein or estradiol (0.01 mu M and 10 mu M as maximum clinically applicable dose) and irradiation with different doses (0-4 Gy). The differentiation state of fibroblasts after combined therapy was analyzed. Results: A549 cells expressing mutated TP53 were more radioresistant than TP53 wild-type cells. Incubation of nonfunctional TP53 cells with genistein or estradiol increased radiosensitivity in both tested concentrations. By contrast, radiosensitivity of A549 with wild-type TP53 and DF-18 was not altered by hormonal incubation. In DF-18 radiation induced growth arrest that was not increased by additional hormonal incubation. Conclusion: NSCLC cells with nonfunctional TP53 might be sensitized against radiation by genistein or estradiol. As genistein is better tolerable than estradiol in patients, additional studies are warranted to assess potential gains of this combination therapy."],["dc.identifier.doi","10.1007/s00066-007-1561-0"],["dc.identifier.isi","000245452600006"],["dc.identifier.pmid","17406801"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51725"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","0179-7158"],["dc.title","Radiosensitization dependent on p53 function in bronchial carcinoma cells by the isoflavone genistein and estradiol in vitro"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","447"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","International Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","452"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Prinz, Marco"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Weiss, Elisabeth"],["dc.date.accessioned","2021-06-01T10:49:17Z"],["dc.date.available","2021-06-01T10:49:17Z"],["dc.date.issued","2005"],["dc.identifier.doi","10.1007/s10147-005-0529-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86233"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1437-7772"],["dc.relation.issn","1341-9625"],["dc.title","Paraganglioma of the cerebellum: case report and review of the literature"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","643"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","International Journal of Radiation Biology"],["dc.bibliographiccitation.lastpage","657"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Luecke, Eva-Maria"],["dc.contributor.author","Peters, Kerstin"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T11:20:07Z"],["dc.date.available","2018-11-07T11:20:07Z"],["dc.date.issued","2008"],["dc.description.abstract","Purpose: Despite proven antitumor activity of gemcitabine in chemoradiotherapy of advanced head and neck cancer, many authors refer to severe acute and late local and haematological toxicity. Fludarabine does imply nearly the same mechanisms of action as gemcitabine, inhibiting various enzymes involved in DNA replication. This investigation focuses on the combined effect of either fludarabine or gemcitabine and radiation on human squamous carcinoma cell lines in vitro, providing data for future decisions on head and neck chemoradiotherapy regimen. Materials and methods: ZMK-1, A549, BW-225, GR-145, OH-65 and CaSki cell lines were incubated with either drug at defined schedules and irradiated at a single fraction dose of 2 Gy every 24 hours up to 8 Gy. Cytotoxic effects were measured by colony-forming assays, quantitative determination of apoptosis and isobologram analysis. Results: Incubation of fludarabine led to a radiosensitizing effect in the A549, CaSki and ZMK-1 cell lines and an additive effect in the BW-225, GR-145 and OH-65 cell lines. Treatment with gemcitabine only indicated significant radiosensitization in the CaSki cell line in combination with augmented resistance against gemcitabine application alone. Conclusions: Our results reveal a potential radiosensitizing effect of fludarabine and its possible application in chemoradiotherapy of advanced head and neck carcinoma and possibly other tumor entities."],["dc.identifier.doi","10.1080/09553000802241754"],["dc.identifier.isi","000258002000003"],["dc.identifier.pmid","18661380"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55460"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","0955-3002"],["dc.title","The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1067"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.lastpage","1074"],["dc.bibliographiccitation.volume","65"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Martin, Alexios"],["dc.contributor.author","Florez, Rodrigo"],["dc.contributor.author","Kahler, Elke"],["dc.contributor.author","Nitsche, Mirko"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Steiner, Wolfgang"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T09:32:05Z"],["dc.date.available","2018-11-07T09:32:05Z"],["dc.date.issued","2006"],["dc.description.abstract","Purpose: The aim of this study was to evaluate the efficacy of adjuvant radiotherapy after transoral laser microsurgery for advanced recurrent head-and-neck squamous cell carcinoma (HNSCC). Patients and Methods: Between 1988 and 2000, 37 patients with advanced local recurrences (23 local and 14 locoregional recurrences) of HNSCC without distant metastases were treated in curative intent with organ-preserving transoral laser microsurgery and adjuvant radiotherapy (before 1994 split-course radiotherapy with carboplatinum, after 1994 conventional radiotherapy). Initial therapy of the primary (8.1% oral cavity, 35.1% oropharynx, 13.5% hypopharynx, and 43.3% larynx) before relapse was organ-preserving transoral laser microsurgery without any adjuvant therapy. Results: After a median follow-up of 124 months, the 5-year overall survival rate was 21.3%, the loco-regional control rate 48.3%, respectively. In multivariate analysis, stage of original primary tumor (Stage I/II vs. Stage III/IV), and patient age (< 58 years vs. >= 58 years) showed statistically significant impact on prognosis. In laryngeal cancer, larynx preservation rate after treatment for recurrent tumor was 50% during follow-up. Conclusion: Our data show that organ-preserving transoral laser microsurgery followed by adjuvant radiotherapy is a curative option for patients who have advanced recurrence after transoral laser surgery and is an alternative to radical treatment. (c) 2006 Elsevier Inc."],["dc.identifier.doi","10.1016/j.ijrobp.2006.03.007"],["dc.identifier.isi","000238878800015"],["dc.identifier.pmid","16750331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31668"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0360-3016"],["dc.title","Long-term follow-up after transoral laser microsurgery and adjuvant radiotherapy for advanced recurrent squamous cell carcinoma of the head and neck"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]